Israel
· Delayed Price · Currency is ILS · Price in ILA XTL Biopharmaceuticals Statistics
Total Valuation
TLV:XTLB has a market cap or net worth of ILS 48.48 million. The enterprise value is 42.08 million.
| Market Cap | 48.48M |
| Enterprise Value | 42.08M |
Important Dates
The next estimated earnings date is Wednesday, March 26, 2025.
| Earnings Date | Mar 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TLV:XTLB has 881.39 million shares outstanding. The number of shares has increased by 7.97% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 881.39M |
| Shares Change (YoY) | +7.97% |
| Shares Change (QoQ) | +31.89% |
| Owned by Insiders (%) | 14.94% |
| Owned by Institutions (%) | 2.72% |
| Float | 749.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 189.69 |
| PB Ratio | 2.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.72 |
| EV / Sales | 246.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.81
| Current Ratio | 0.81 |
| Quick Ratio | 0.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.16 |
Financial Efficiency
Return on equity (ROE) is -25.70% and return on invested capital (ROIC) is -23.73%.
| Return on Equity (ROE) | -25.70% |
| Return on Assets (ROA) | -16.33% |
| Return on Invested Capital (ROIC) | -23.73% |
| Return on Capital Employed (ROCE) | -22.90% |
| Revenue Per Employee | 34,199 |
| Profits Per Employee | -785,094 |
| Employee Count | 5 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.14% in the last 52 weeks. The beta is 1.06, so TLV:XTLB's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +57.14% |
| 50-Day Moving Average | 6.03 |
| 200-Day Moving Average | 7.74 |
| Relative Strength Index (RSI) | 43.76 |
| Average Volume (20 Days) | 699,988 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TLV:XTLB had revenue of ILS 170,996 and -3.93 million in losses. Loss per share was -0.01.
| Revenue | 170,996 |
| Gross Profit | 170,996 |
| Operating Income | -5.80M |
| Pretax Income | -3.93M |
| Net Income | -3.93M |
| EBITDA | n/a |
| EBIT | -5.80M |
| Loss Per Share | -0.01 |
Balance Sheet
| Cash & Cash Equivalents | 6.39M |
| Total Debt | n/a |
| Net Cash | 6.39M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 21.25M |
| Book Value Per Share | 0.02 |
| Working Capital | -1.78M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -3,391.30% |
| Pretax Margin | -2,295.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLV:XTLB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.97% |
| Shareholder Yield | -7.97% |
| Earnings Yield | -8.10% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on June 22, 2009. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jun 22, 2009 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
TLV:XTLB has an Altman Z-Score of -22.47. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.47 |
| Piotroski F-Score | n/a |